Feagan 2000.

Methods	Randomized, double‐blind, placebo controlled trial involving one administration of placebo or vedolizumab at various doses. Evaluated 30 days after administration of study medication.
Participants	29 patients (17M/12F) with diagnosed ulcerative colitis (moderately severe as defined by a minimum Mayo Clinical score of ≥5, ≥3 bowel movements per day and evidence of active disease on endoscopy). One patient was withdrawn for not meeting inclusion criteria.
Interventions	Vedolizumab 0.15mg/kg SC (n=5), vedolizumab 0.15mg/kg IV (n=5), vedolizumab 0.5mg/kg IV (n=5), vedolizumab 2.0mg/kg IV (n=5) or placebo (n=8)
Outcomes	Endoscopic response (measured by a modified Baron score), Mayo Clinical score and adverse events
Notes	Available as an abstract only
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated
Allocation concealment (selection bias)	Low risk	Centralized randomization
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐blind Identical placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	No attrition
Selective reporting (reporting bias)	Low risk	All outcomes were reported
Other bias	Low risk	No other issues